Clinical trial
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With…
NCT00338117 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00338117 |
|---|---|
| Title | Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease |
| Official title | A European Multi-Center Study to Determine the Safety and Efficacy of Galanthamine Hydrobromide 40mg/Day (32 mg /Day GAL Base, Tid Dose Regimen) in Patients Diagnosed With Alzheimer-Type Dementia |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Shire Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease, Dementia |
| Intervention type | Drug |
| Interventions | Galantamine hydrobromide |
| Enrollment | 554 |
| Start date | Aug 1, 1995 |
| Completion | May 1, 1997 |
| First posted | Jun 20, 2006 |
| Last update posted | Apr 28, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: